Yes, there is a large number of new antibiotics in the pipeline. These include such agents as glycopeptides (such as oritavancin and telavancin), lipoglycopeptide (such as dalbavancin), oxazolidinones (such as linezolid and tedizolid), lincosamides (such as clindamycin), streptogramins (such as quinupristin/dalfopristin), and tetracycline analogs (such as tigecycline).